Kala Pharmaceuticals to Report First Quarter 2019 Financial Results and Host Conference Call
The dial-in numbers to access the conference call are 866-300-4091 (domestic) or 703-736-7433 (international) using the conference ID 2881526. To access a live webcast and subsequent archived recording of the presentation, please visit “Events” in the “Investors” section of the Kala website at http://kalarx.com/.
About
Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary AMPPLIFY™ mucus-penetrating particle (MPP) Drug Delivery Technology, with an initial focus on the treatment of eye diseases. Kala has applied the AMPPLIFY Drug Delivery Technology to a corticosteroid, loteprednol etabonate (LE), designed for ocular applications, resulting in recently approved INVELTYS™ for the treatment of inflammation and pain following ocular surgery and its lead product candidate, KPI-121 0.25%, for the temporary relief of the signs and symptoms of dry eye disease, for which a New Drug Application (NDA) has been filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20190502005012/en/
Source:
Investors:
Michael Schaffzin, 212-362-1200
michael@sternir.com
or
Media:
Kari Watson, 781-235-3060
kwatson@macbiocom.com